Looking Beyond Incretins with an Innovative IL-22 Therapy: A Novel Approach to Achieving Quality Weight Loss Without Muscle Loss
Time: 11:30 am
day: Conference Day One
Details:
- Explore how CK-0045, a first-in-class IL-22 analogue being investigated in a Phase 2a study, offers a unique approach to obesity treatment through a novel non-incretin-based mode-of-action in the gut which preserves muscle mass during weight loss
- Understand the potential of CK-0045 to be used as a standalone therapy or in combination with current standard treatments, offering a broader spectrum of benefits that address both weight loss and deeper metabolic improvements
